Arbutus Biopharma Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa
Arbutus Biopharma (Nasdaq: ABUS) announced the FDA lifted a clinical hold on its experimental oral hepatitis B drug, AB-101. The company plans to continue development. AB-101 showed promising results in a Phase 1a/1b trial, with evidence of high receptor occupancy and hepatitis B surface antigen decline in some patients.
Nguyen Tuan (Chief Financial Officer) sold (to issuer) 48,081 shares of Arbutus Biopharma Corp (ABUS) at $5.00 ($0.24M total) on 2026-10-01.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ABUS (Arbutus Biopharma Corp). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent ABUS coverage spans corporate actions, insider activity and regulation.
In the last 30 days, ABUS insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($45.4M). The most active reporter was Sawhney Roger with 1 filing.
The removal of the hold removes a regulatory barrier, likely prompting a positive price reaction.
Positive catalyst as regulatory barrier removed.
Insider sale by the CFO may signal modest concern, but size is small relative to float.
Insider sale may signal reduced confidence, potentially pressuring the stock.
Tender acceptance reduces float and may pressure the share price lower.
AlphAI scores every news story that mentions ABUS with an AI model for sentiment and relevance, and aggregates insider trades from Arbutus Biopharma Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa
2 min readArbutus Biopharma (Nasdaq: ABUS) announced the FDA lifted a clinical hold on its experimental oral hepatitis B drug, AB-101. The company plans to continue development. AB-101 showed promising results in a Phase 1a/1b trial, with evidence of high receptor occupancy and hepatitis B surface antigen decline in some patients.
2 min readNguyen Tuan (Chief Financial Officer) sold (to issuer) 48,081 shares of Arbutus Biopharma Corp (ABUS) at $5.00 ($0.24M total) on 2026-10-01.
1 min readAndroski Lindsay (President and CEO) sold (to issuer) 24,655 shares of Arbutus Biopharma Corp (ABUS) at $5.00 ($0.12M total) on 2026-10-01.
1 min readArbutus Biopharma accepted 46M shares at $5.00 per share in its tender offer, which expired on September 29, 2026. The offer aimed to purchase up to $230M of shares. Roivant Sciences tendered 8.97M shares, receiving $44.84M, and now owns 19.5% of outstanding shares.
2 min readRoivant Sciences Ltd. sold (to issuer) 8,967,383 shares of Arbutus Biopharma Corp (ABUS) at $5.00 ($44.84M total) on 2026-10-01.
1 min readArbutus Biopharma (ABUS) completed a $230M share buyback, retiring 23% of its shares at $5 each. The tender offer was oversubscribed, with 46M shares accepted and 153.3M remaining. Roivant Sciences, holding 19.5%, participated proportionately.
2 min readArbutus Biopharma (ABUS) repurchased 46M shares at $5 each in a $230M tender offer, representing 23% of outstanding shares. The offer was oversubscribed, with a proration rate of 55.6%. Post-offer, 153.3M shares will remain outstanding, according to the company.
1 min readArbutus Biopharma (Nasdaq: ABUS) announced preliminary results of its $230M modified Dutch auction tender offer, purchasing 46M shares at $5.00 each, excluding fees. The offer was oversubscribed, with proration expected. Roivant Sciences, holding 19.5% of shares, maintained its stake. Final results are pending verification.
2 min readArbutus Biopharma (ABUS) launched a $230M stock repurchase tender offer, following strong share price gains. The company trades at a P/E of 6.7x, lower than US equities and biotech peers, but higher than its estimated fair P/E of 1.3x. Analysts forecast declining revenue and earnings, with risks tied to trial results and licensing progress.
2 min read
